Abstract
Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) institutions treated 208 patients with gonadal MGCT in studies CCG 8891/8882, POG 9048/9049. There were 17 Stage II, 17 Stage III, and 43 Stage IV testicular primaries, plus 41 Stage I, 16 Stage II, 58 Stage III, and 16 Stage IV ovarian primaries. Stage II testicular and stage I and II ovarian patients were treated with cisplatin 20 mg/m2/day for 5 days, etoposide 100 mg/m2/day for 5 days and low dose bleomycin 15 units/m2 on day 1 of each course. Stages III and IV ovarian and testicular patients received the same etoposide and bleomycin doses, but the dose of cisplatin was randomly assigned to 20 or 40 mg/m2/day for 5 days (100 mg/m2 or 200 mg/m2 per course). Courses were administered every 21 days for a total of four.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
De Wit R, Roberts JT, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.J Clin Oncol 2001;19:1629–40
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag London Limited
About this paper
Cite this paper
Cullen, J.W. et al. (2002). Low Dose Bleomycin Every Three Weeks with Cisplatin and Etoposide Results in Excellent Event Free and Survival Rates for Children and Adolescents with Gonadal Malignant Germ Cell Tumours (MGCT): a POG/CCG Intergroup Report. In: Harnden, P., Joffe, J.K., Jones, W.G. (eds) Germ Cell Tumours V. Springer, London. https://doi.org/10.1007/978-1-4471-3281-3_23
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3281-3_23
Publisher Name: Springer, London
Print ISBN: 978-1-4471-3283-7
Online ISBN: 978-1-4471-3281-3
eBook Packages: Springer Book Archive